Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Structure of the MET receptor and MET alterations. MET alterations... | Download Scientific Diagram
Frontiers | Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Full article: Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
Targeted Therapies Expanding for MET Dysregulation in NSCLC - ILCN.org (ILCN/WCLC)
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced Non–Small-Cell Lung Cancer
HER3 phosphorylation in cancer cells with MET amplification is... | Download Scientific Diagram
The role of MET in chemotherapy resistance | Oncogene
Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET–positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib - Journal
Acquired Resistance of <i xmlns="">MET</i>-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
The multiple paths towards MET receptor addiction in cancer | Oncogene
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor - ScienceDirect
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Cancers | Free Full-Text | Overview of Molecular Detection Technologies for MET in Lung Cancer
Cancers | Free Full-Text | The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
Implementation of MET Molecular Testing in the Clinic: Latest Evidence for Mesenchymal–Epithelial Transition Inhibitors in Non-small Cell Lung Cancer - European Medical Journal
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
IJMS | Free Full-Text | Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Schematic representation of MET signaling blockade by capmatinib.... | Download Scientific Diagram
Capmatinib chez les patients atteints d'un CBNPC avancé avec haut niveau d' amplification de MET : résultats de l'étude de phase II GEOMETRY mono-1 CHICAGO 2020 - E-journal | Edimark.fr
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
